Clinical trial / 2013
Curcuminoids lowered fasting glucose and HbA1c in overweight patients with type 2 diabetes.
A double-blind, randomized, placebo-controlled trial assigned 100 overweight or obese patients with type 2 diabetes to receive 300 mg daily of curcuminoids or placebo for three months. Curcuminoid supplementation significantly reduced fasting blood glucose (p < 0.01), HbA1c (p = 0.031), and homeostatic model assessment of insulin resistance (p < 0.01). Participants receiving curcuminoids also experienced significant reductions in serum free fatty acids and triglycerides alongside elevated lipoprotein lipase activity.
- Study type
- Randomized controlled trial
- Who was studied
- 100 overweight or obese adults with type 2 diabetes
- What was measured
- Fasting blood glucose, HbA1c, insulin resistance, and serum lipids
THE PAPER
Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial.
Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, Li XX, Sun CH. Mol Nutr Food Res, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.